←
Matt Banghart524 posts
Matt Banghart avatar

Matt Banghart

@chromism

Chemical Neurobiologist at UCSD

◷ Joined October 2009▧ 23 Photos and videos
Matt Banghart avatar
Matt Banghart@chromism·31 Aug 2023

new pub from the lab describing a strategy for caging amidated peptides (most neuropeptides); applied to CCK, oxytocin, substance P, and GRP pubs.acs.org/doi/10.1021/jac… congrats to all authors, incl. @XIANGMa13 @jennyxinyi & 1st author aryanna layden, now starting her PhD at Berkeley

Olivier George avatar
⟳ Matt Banghart retweeted
Olivier George@brainaddiction·19 Feb 2025

It's clear that many do not understand what @NIH-funded research does to improve health. It's time to revive a study published 10 years ago that provides incredible information about this. link in the comment Every single new drug approved by the FDA from 2010–2016 was built on NIH-funded research—that’s all 210 drugs. But what the public sees is just the tip of the iceberg. Pharma takes credit for the final product, but beneath each drug developed, there are ~20 years of basic research, and 90% of the cost is from basic research funded by the NIH, which discovers drug targets, understands disease mechanisms, and creates life-saving treatments. Figuring out how cancer evades the immune system, how addiction rewires the brain, and how heart disease develops is the role of the NIH, creating the foundation for the breakthrough drugs that come 20 years later, and the NIH does all that with only 0.8% of the US budget. Without NIH, there would be no cancer immunotherapy, no anti-overdose medication, no anti-heart attack or stroke medication, no cutting-edge treatments. If NIH funding is cut, the iceberg will melt. That means fewer cures, more suffering, and more lives lost. The science beneath the surface keeps us afloat. Invest in NIH. Invest in life

Post attachment
Matt Banghart avatar
⟳ Matt Banghart retweeted
Matt Banghart@chromism·17 Feb 2025

Curious about the placebo effect, especially placebo pain relief? If so, check out our pre-print on placebo analgesia in mice bit.ly/3QlktPq, in which we ask how pain-modulatory neural circuits become activated in the brain to suppress pain in the absence of a drug. 1/9

Matt Banghart avatar
Matt Banghart@chromism·17 Feb 2025

Congratulations to the authors, especially Giulia Livrizzi, who conducted the vast majority of this work while a PhD student in the lab.

Matt Banghart avatar
Matt Banghart@chromism·17 Feb 2025

Understanding the neural basis of placebo will help us develop better therapies for pain and depression. Capitalizing on placebo can reduce our reliance on dangerous drugs, whereas reducing placebo in clinical trials will help reveal the true efficacy of emerging therapies. 9/9

Matt Banghart avatar
Matt Banghart@chromism·17 Feb 2025

Interestingly, conditioning appears to prime this circuit through a poorly understood process involving peptidergic plasticity. 8/9

Matt Banghart avatar
Matt Banghart@chromism·17 Feb 2025

Our findings suggest that the vlPAG is a central node in a closed, negative feedback loop through which incoming noxious sensory information is shaped by endogenous opioids to match expectations based on prior experience. 7/

Matt Banghart avatar
Matt Banghart@chromism·17 Feb 2025

Using in vivo photopharmacology, we locally photo-activated PhNX, our “caged” naloxone bit.ly/4b2XTEI, to establish that this rapidly evoked opioid peptide signaling in the vlPAG is necessary for placebo pain relief. 6/9

Post attachment
Matt Banghart avatar
Matt Banghart@chromism·17 Feb 2025

Using a genetically-encoded opioid sensor developed by @LinTianPhD bit.ly/4i2jHTf, we discovered that the painful test stimulus evokes opioid peptide release in the vlPAG within seconds, but this was only detected after morphine conditioning. 5/9

Post attachment
Matt Banghart avatar
Matt Banghart@chromism·17 Feb 2025

Using Ca2+ recordings and LOF manipulations, we established an essential role for vlPAG neurons that project to the RVM in both morphine and placebo analgesia. In contrast, we found that cortical input to the vlPAG is only critical for placebo. 4/9

Post attachment
Matt Banghart avatar
Matt Banghart@chromism·17 Feb 2025

Although we only conditioned the mice to suppress a paw withdrawal (antinociception), the placebo effect extended to unconditioned pain-related behaviors, such as avoidance and escape, indicating that the conditioning protocol produces a general state of analgesia. 3/9

Post attachment
Matt Banghart avatar
Matt Banghart@chromism·17 Feb 2025

To achieve placebo analgesia in mice, we conditioned them with morphine. This yielded ~50% of the morphine effect on placebo trials! Like most placebo analgesia in humans, the placebo in mice relies on endogenous opioid neuropeptide signaling. 2/9

Post attachment
Sung Han avatar
⟳ Matt Banghart retweeted
Sung Han@iamhans·22 Jul 2024

1/6 Exciting news! Our paper is now online in @CellCellPress! We've developed PRESYNAPTIC sensor and silencer for peptidergic transmission. The sensor detects LDCV release events, and the silencer specifically degrades neuropeptides inside the LDCV. authors.elsevier.com/a/1jTSj…

Post attachment